scispace - formally typeset
G

Guillermo Garcia-Manero

Researcher at University of Texas MD Anderson Cancer Center

Publications -  25
Citations -  16186

Guillermo Garcia-Manero is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Leukemia & Myeloid leukemia. The author has an hindex of 19, co-authored 25 publications receiving 14107 citations. Previous affiliations of Guillermo Garcia-Manero include University of Texas at Austin.

Papers
More filters
Journal ArticleDOI

Guidelines for the use and interpretation of assays for monitoring autophagy

Daniel J. Klionsky, +1287 more
- 01 Apr 2012 - 
TL;DR: These guidelines are presented for the selection and interpretation of methods for use by investigators who aim to examine macroautophagy and related processes, as well as for reviewers who need to provide realistic and reasonable critiques of papers that are focused on these processes.
Journal ArticleDOI

Revised International Prognostic Scoring System for Myelodysplastic Syndromes

Peter L. Greenberg, +33 more
- 20 Sep 2012 - 
TL;DR: This revised IPSS-R comprehensively integrated the numerous known clinical features into a method analyzing MDS patient prognosis more precisely than the initial IPSS and should prove beneficial for predicting the clinical outcomes of untreated MDS patients and aiding design and analysis of clinical trials in this disease.
Journal ArticleDOI

Clinical effect of point mutations in myelodysplastic syndromes.

Rafael Bejar, +10 more
- 30 Jun 2011 - 
TL;DR: Mutations in TP53, EZH2, ETV6, RUNX1, and ASXL1 are predictors of poor overall survival in patients with myelodysplastic syndromes, independently of established risk factors.
Journal ArticleDOI

Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies.

Jean Pierre J. Issa, +10 more
- 01 Mar 2004 - 
TL;DR: It is concluded that decitabine is effective in myeloid malignancies, and low doses are as or more effective than higher doses.
Journal ArticleDOI

Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies

Omar Abdel-Wahab, +26 more
- 02 Jul 2009 - 
TL;DR: In this paper, the mutational status of TET1, TET2, and TET3 in myeloproliferative neoplasms (MPNs), chronic myelomonocytic leukemia (CMML), and acute myeloid leukemia (AML) was evaluated.